TY - JOUR AU - Juhász, Lilla AU - Lőrincz, Hajnalka AU - Szentpéteri, Anita AU - Nádró, Bíborka AU - Varga, E. AU - Paragh, György AU - Harangi, M. TI - ELEVATED SPHINGOSINE 1-PHOSPHATE LEVEL IN FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS JF - ATHEROSCLEROSIS J2 - ATHEROSCLEROSIS VL - 379 PY - 2023 IS - S1 SP - S118 EP - S118 SN - 0021-9150 UR - https://m2.mtmt.hu/api/publication/34738471 ID - 34738471 LA - English DB - MTMT ER - TY - JOUR AU - Lőrincz, Hajnalka AU - Ratku, Balázs AU - Ötvös, T. AU - Szentpéteri, Anita AU - Seres, Ildikó AU - Paragh, György AU - Harangi, Mariann AU - Somodi, Sándor TI - CORRELATIONS BETWEEN SERUM AFAMIN AND LIPID PARAMETERS IN OBESE TYPE 2 DIABETIC PATIENTS JF - ATHEROSCLEROSIS J2 - ATHEROSCLEROSIS VL - 379 PY - 2023 IS - S1 SP - S104 EP - S104 SN - 0021-9150 UR - https://m2.mtmt.hu/api/publication/34732660 ID - 34732660 LA - English DB - MTMT ER - TY - JOUR AU - Szentimrei, R. AU - Lőrincz, Hajnalka AU - Szentpéteri, Anita AU - Varga, V.E. AU - Harangi, Mariann AU - Seres, I. AU - P. Szabó, Réka AU - Nemes, Balázs AU - Paragh, György TI - Increased serum PEDF levels and altered lipid profile after renal transplantation in patients with end-stage renal disease JF - ATHEROSCLEROSIS J2 - ATHEROSCLEROSIS VL - 379 PY - 2023 SP - S157 EP - S157 PG - 1 SN - 0021-9150 DO - 10.1016/j.atherosclerosis.2023.06.534 UR - https://m2.mtmt.hu/api/publication/34729478 ID - 34729478 LA - English DB - MTMT ER - TY - JOUR AU - Juhász, Lilla AU - Lőrincz, Hajnalka AU - Szentpéteri, Anita AU - Tóth, Nóra AU - Varga, Éva AU - Paragh, György AU - Harangi, Mariann TI - Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 20 PG - 14 SN - 1661-6596 DO - 10.3390/ijms242015308 UR - https://m2.mtmt.hu/api/publication/34215397 ID - 34215397 AB - Stromal cell-derived factor-1 (SDF-1) is a chemokine that exerts multifaceted roles in atherosclerosis. However, its association with hyperlipidemia is contradictory. To date, serum SDF-1 and its correlations with lipid fractions and subfractions in heterozygous familial hypercholesterolemia (HeFH) have not been investigated. Eighty-one untreated patients with HeFH and 32 healthy control subjects were enrolled in the study. Serum SDF-1, oxidized LDL (oxLDL) and myeloperoxidase (MPO) were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Significantly lower serum SDF-1 was found in HeFH patients compared to healthy controls. Significant negative correlations were detected between serum total cholesterol, triglycerides, LDL-cholesterol (LDL-C), apolipoprotein B100 (ApoB100) and SDF-1. Furthermore, serum SDF-1 negatively correlated with VLDL and IDL, as well as large LDL and large and intermediate HDL subfractions, while there was a positive correlation between mean LDL-size, small HDL and SDF-1. SDF-1 negatively correlated with oxLDL and MPO. A backward stepwise multiple regression analysis showed that the best predictors of serum SDF-1 were VLDL and oxLDL. The strong correlation of SDF-1 with lipid fractions and subfractions highlights the potential common pathways of SDF-1 and lipoprotein metabolism, which supports the role of SDF-1 in atherogenesis. LA - English DB - MTMT ER - TY - JOUR AU - Szentimrei, R. AU - Lőrincz, Hajnalka AU - Szentpéteri, Anita AU - Varga, V.E. AU - Seres, Ildikó AU - Varga, Éva AU - Nemes, Balázs AU - Harangi, Mariann AU - Paragh, György TI - Assessment of amino-terminal C-type natriuretic peptide serum level and its correlation with high-density lipoprotein structure and function in patients with end stage renal disease before and after kidney transplantation JF - CHEMICO-BIOLOGICAL INTERACTIONS J2 - CHEM-BIOL INTERACT VL - 385 PY - 2023 IS - 1 PG - 8 SN - 0009-2797 DO - 10.1016/j.cbi.2023.110749 UR - https://m2.mtmt.hu/api/publication/34214638 ID - 34214638 LA - English DB - MTMT ER - TY - JOUR AU - Sztanek, Ferenc AU - Tóth, László AU - Molnár, Ágnes AU - Bak-Csiha, Sára AU - Szentpéteri, Anita AU - Lőrincz, Hajnalka AU - Nagy, Attila Csaba AU - Paragh, György AU - Harangi, Mariann TI - 520 $aA 2-es típusú cukorbetegségben (T2DM) az inzulinrezisztencia és az elhízás, valamint a kóros lipideltérések között JF - DIABETOLOGIA HUNGARICA J2 - DIABETOLOGIA HUNGARICA VL - 31 PY - 2023 IS - Suppl_1 SP - 71 EP - 72 PG - 2 SN - 1217-372X UR - https://m2.mtmt.hu/api/publication/34087449 ID - 34087449 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Molnár, Ágnes AU - Lőrincz, Hajnalka AU - Szentpéteri, Anita AU - Harangi, Mariann AU - Paragh, György AU - Sztanek, Ferenc TI - Az aerob edzés hatása az oxidatív stressz és az endotheldiszfunkció markereire diabéteszes polyneuropathiás betegekben JF - DIABETOLOGIA HUNGARICA J2 - DIABETOLOGIA HUNGARICA VL - 31 PY - 2023 IS - Suppl_1 SP - 51 SN - 1217-372X UR - https://m2.mtmt.hu/api/publication/34069206 ID - 34069206 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Sztanek, Ferenc AU - Jakab, Á.A. AU - Molnár, Ágnes AU - Szentpéteri, Anita AU - Lőrincz, H. AU - Paragh, György AU - Harangi, Mariann TI - Effect of semaglutide on lipoprotein subfractions and chemerin levels in type 2 diabetic patients JF - ATHEROSCLEROSIS J2 - ATHEROSCLEROSIS VL - 355 PY - 2022 SP - 120 SN - 0021-9150 DO - 10.1016/j.atherosclerosis.2022.06.582 UR - https://m2.mtmt.hu/api/publication/33204286 ID - 33204286 LA - English DB - MTMT ER - TY - JOUR AU - Czókolyová, Monika AU - Hamar, Attila AU - Karancsiné Pusztai, Anita AU - Tajti, Gábor AU - Végh, Edit AU - Pethő, Zsófia AU - Bodnár, Nóra AU - Horváth, Ágnes AU - Boglárka, Soós AU - Szamosi, Szilvia AU - Szentpéteri, Anita AU - Seres, Ildikó AU - Harangi, Mariann AU - Paragh, György AU - Kerekes, György AU - Bodoki, Levente AU - Katalin, Hodosi AU - Tamás, Seres AU - Panyi, György AU - Szekanecz, Zoltán AU - Szűcs, Gabriella TI - Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis JF - BIOMOLECULES J2 - BIOMOLECULES VL - 12 PY - 2022 IS - 10 SN - 2218-273X DO - 10.3390/biom12101483 UR - https://m2.mtmt.hu/api/publication/33153228 ID - 33153228 AB - Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compared with anti-tumor necrosis factor α (TNF-α) therapy. In our study, we evaluated lipids and other metabolic markers in relation to vascular function and clinical markers in RA patients undergoing one-year tofacitinib therapy. Patients and methods: Thirty RA patients treated with either 5 mg or 10 mg bid tofacitinib were included in a 12-month follow-up study. Various lipids, paraoxonase (PON1), myeloperoxidase (MPO), thrombospondin-1 (TSP-1) and adipokine levels, such as adiponectin, leptin, resistin, adipsin and chemerin were determined. In order to assess flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and arterial pulse-wave velocity (PWV) ultrasonography were performed. Assessments were carried out at baseline, and 6 and 12 months after initiating treatment. Results: One-year tofacitinib therapy significantly increased TC, HDL, LDL, APOA, APOB, leptin, adipsin and TSP-1, while significantly decreasing Lp(a), chemerin, PON1 and MPO levels. TG, lipid indices (TC/HDL and LDL/HDL), adiponectin and resistin showed no significant changes. Numerous associations were found between lipids, adipokines, clinical markers and IMT, FMD and PWV (p < 0.05). Regression analysis suggested, among others, association of BMI with CRP and PWV (p < 0.05). Adipokines variably correlated with age, BMI, CRP, CCP, FMD, IMT and PWV, while MPO, PON1 and TSP-1 variably correlated with age, disease duration, BMI, RF and PWV (p < 0.05). Conclusions: JAK inhibition by tofacitinib exerts balanced effects on lipids and other metabolic markers in RA. Various correlations may exist between metabolic, clinical parameters and vascular pathophysiology during tofacitinib treatment. Complex assessment of lipids, metabolic factors together with clinical parameters and vascular pathophysiology may be utilized in clinical practice to determine and monitor the CV status of patients in relation with clinical response to JAK inhibition. LA - English DB - MTMT ER - TY - JOUR AU - Czókolyová, Monika AU - Karancsiné Pusztai, Anita AU - Végh, Edit AU - Horváth, Ágnes AU - Szentpéteri, Anita AU - Hamar, Attila AU - Szamosi, Szilvia AU - Hódosi, Katalin AU - Domján, Andrea AU - Szántó, Sándor Zoltán AU - Kerekes, György AU - Seres, Ildikó AU - Harangi, Mariann AU - Paragh, György AU - Szekanecz, Éva AU - Szekanecz, Zoltán AU - Szűcs, Gabriella TI - Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology JF - BIOMOLECULES J2 - BIOMOLECULES VL - 11 PY - 2021 IS - 10 SP - 1 EP - 15 PG - 15 SN - 2218-273X DO - 10.3390/biom11101535 UR - https://m2.mtmt.hu/api/publication/32490017 ID - 32490017 N1 - 323654 AB - Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p < 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p < 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p < 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology. LA - English DB - MTMT ER -